Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Christyn Edmundson, MD
Shared Goals, Shared Gains: Align With Patient Preferences
Gil I. Wolfe MD, FAAN
The 2-Point Signal: Apply ≥2-Point Rule
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
Neelam Goyal, MD
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
Vera Bril, MD
Preventing Myasthenic Crisis: Early Signs and Critical Interventions
Hans Katzberg, MD
Diagnostic Advances in gMG: Effective Tools and Techniques
Managing Side Effects in FcRn Therapy: Best Practices for gMG
Nicholas J. Silvestri, MD
Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles
A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained
Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management
Treatment Advances in Generalized Myasthenia Gravis: Addressing the Nuances of its Underlying Immunopathology
Ocular to Generalized MG: How and Why the Disease Evolves
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
Jonathan Strober, MD
Living with gMG: Navigating Personal, Professional, and Mental Health Challenges
New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.